International Patent: ST2-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF

GENEVA, Sept. 18 -- SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD. filed a patent application (CN2025/080755) for “ST2-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF”. With publication no. WO/2026/183744, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/28

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....